Earnings ·
Zevra reports Q3 net revenue of $37.8 million and net income of $0.31 per share
ZVRAZevra Therapeutics, Inc.
Zevra Therapeutics reported third-quarter 2026 financial results, posting $37.8 million in net revenue, a 45% increase from the prior-year period, driven by $34.0 million in sales of its Niemann-Pick disease treatment MIPLYFFA. The company recorded a net income of $19.2 million, or $0.31 per basic share, compared to a net loss of $0.5 million in Q3 2025. Operating expenses rose to $24.1 million due to increased commercial and infrastructure costs. Zevra ended the quarter with a cash position of $270.9 million and provided updates on its pipeline, including enrollment progress for celiprolol and plans to file a supplemental New Drug Application for MIPLYFFA in Q1 2027. The company operates as a commercial-stage biopharmaceutical firm focused on developing therapies for rare diseases.